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SUMMARY
It is well known that four major risk factors for atherosclerosis include diabetes mellitus,
hypertension, hyperlipidemia and smoking. Among these risk factors, management of
hyperlipidemia, especially hyper-LDL cholesterolemia, has become to be strictly achieved by the
appearance of statins. Many randomized control trials using statins have been performed, and
the effectiveness in reduction of cardiovascular events is clearly established. Under these
circumstances, we planed and performed the Shikoku Hyperlipidemia Study（SHS）to reveal
how do we treat and what degree do we strictly manage patients with hyperlipidemia.
Evidence obtained by The SHS study were 1）unmeasurement rates of serum cholesterol
levels in categories B and C were 28.1% and 18.2%, respectively, 2）among patients in
categories B and C who need to be treated by drugs, only 35.5% and 35.9% of patients in
categories B and C were treated, respectively, 3）drugs medicated in such patients were
mostly statins and a single kind of statin was administered, and 4）rate of successfully
treated patients in category B was 40～50% and that in category C was 20～30%. When
this analysis, which was performed based upon guideline published in 1997, was re-analyzed
by new guideline published in 2002, rates of successfully treated patients in categories A, B1,
B2, B3, B4, and C were 91.7%, 66.1%, 77.6%, 42.9%, 60.7%, and 32.6%, respectively.
Pleiotropic effects of statins have been postulated, however, a couple of issues are still
elusive ; that is, 1）can statins suppress the progression of atherosclerosis by the mechanism
other than cholesterol lowering in humans? and 2）should statins be administered to patients
for secondary and primary preventions against cardiovascular events to anticipate pleiotropic
effects of statins?. Evidence obtained so far suggest that statins exert its pleiotropic effects
via 1）enhancement of NO production by phosphorylation of eNOS, Akt and PI 3 kinase, 2）
inhibition of Ras activation by reduction of farnesyl-pyrophosphate, and 3）inhibition of Rho
family activation by reduction of geranylgeranyl-pyrophosphate, and that Heart Protection
Study and ASCOT-LLA study revealed that additive benefits can be elicited when
hyperlipidemic patients bearing many risk factors including diabetes mellitus were treated
with statins.
In conclusion, we need to treat patients with hyperlipidemia in consideration of the
quality and quantity of risk factors for cardiovascular diseases.
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